MTSR Metsera, Inc. Common Stock

$70.50

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Metsera, Inc. Common Stock

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. The company is headquartered in New York, New York.

Website: https://metsera.com

Sector
TECHNOLOGY
Industry
GENERAL
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
nan
Address
NONE
Valuation
Market Cap
$3.09B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
0.00
Performance
EPS
$nan
Dividend Yield
—
Profit Margin
0.00%
ROE
0.00%
Technicals
50D MA
$28.43
200D MA
$28.43
52W High
$32.81
52W Low
$12.30
Fundamentals
Shares Outstanding
15M
Target Price
$nan
Beta
nan

MTSR EPS Estimates vs Actual

● Estimated
● Actual

MTSR News & Sentiment

Nov 21, 2025 • CNBC SOMEWHAT-BULLISH
Eli Lilly hits $1 trillion market value, a first for a health-care company
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
Nov 21, 2025 • Motley Fool NEUTRAL
This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase
The drugmaker may not continue to lag the market for much longer.
Nov 20, 2025 • Zacks Commentary NEUTRAL
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Nov 18, 2025 • Motley Fool NEUTRAL
Can AI Drive Peloton's Comeback?
The market is hopping with interesting news.
Nov 18, 2025 • Zacks Commentary NEUTRAL
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Nov 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
Sentiment Snapshot

Average Sentiment Score:

0.134
50 articles with scored sentiment

Overall Sentiment:

Neutral

MTSR Reported Earnings

Jul 28, 2025
Jun 30, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.66
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
May 12, 2025
Mar 31, 2025 (Pre market)
0.01 Surprise
  • Reported EPS: $-1.03
  • Estimate: $-1.04
  • Whisper: —
  • Surprise %: 1.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
-2.72 Surprise
  • Reported EPS: $-3.52
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: -340.0%

Financials